,
4 tweets,
2 min read
Read on Twitter
Summary of results from iDCL trial of Tandem/Dexcom hybrid-closed loop system at #ADA2019
Included: 14 yrs and older, T1D > 1 yr
Minimal entry restrictions
170 subjects enrolled: Closed loop (112 ppl), sensor-augmented pump (56 ppl) #diabetes #t1d #closedloop
Included: 14 yrs and older, T1D > 1 yr
Minimal entry restrictions
170 subjects enrolled: Closed loop (112 ppl), sensor-augmented pump (56 ppl) #diabetes #t1d #closedloop
Subject characteristics: 33 years old; A1c 7.4% baseline; 20-25% MDI; 70% current CGM user;
Median diabetes duration 15 yrs
Median diabetes duration 15 yrs
Outcomes:
100% of people completed study
Time in range increased 11% (to 71% in closed loop group); A1c decreased -0.33%; Mean glucose decreased 13 mg/dL;
Participants used CGM 97% time; 92% time with closed loop active.
100% of people completed study
Time in range increased 11% (to 71% in closed loop group); A1c decreased -0.33%; Mean glucose decreased 13 mg/dL;
Participants used CGM 97% time; 92% time with closed loop active.
Closed loop system benefits began in month 1 and were consistently sustained.
Adverse events:
1 DKA in Closed Loop due to infusion site failure;
Use of study device was suspended in 33 participants for up to 4 weeks in March 2019 due to software issue
Adverse events:
1 DKA in Closed Loop due to infusion site failure;
Use of study device was suspended in 33 participants for up to 4 weeks in March 2019 due to software issue
